C4 Therapeutics (CCCC) vs. Its Competitors Head to Head Survey

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare C4 Therapeutics to related businesses based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, profitability, dividends and risk.

Earnings and Valuation

This table compares C4 Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
C4 Therapeutics $32.28 million -$104.99 million -3.83
C4 Therapeutics Competitors $747.77 million $11.56 million -18.80

C4 Therapeutics’ rivals have higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares C4 Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
C4 Therapeutics -282.22% -37.71% -26.42%
C4 Therapeutics Competitors -12,224.09% -202.33% -31.23%

Risk and Volatility

C4 Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the S&P 500. Comparatively, C4 Therapeutics’ rivals have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for C4 Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4 Therapeutics 1 1 5 0 2.57
C4 Therapeutics Competitors 9923 15313 45658 1602 2.54

C4 Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 207.97%. As a group, “Biotechnology” companies have a potential upside of 126.39%. Given C4 Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than its rivals.

Summary

C4 Therapeutics beats its rivals on 9 of the 13 factors compared.

C4 Therapeutics Company Profile

(Get Free Report)

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.